Movano

About Movano

Movano Health, operating as a public company since its founding in 2018, is focused on developing healthcare solutions that merge medical-grade data with consumer-friendly wearable devices. The company was established by Michael Leabman, an MIT-educated serial entrepreneur with deep expertise in RF-based technologies and over 200 patents. Leabman, serving as CTO, brought a vision to use radio frequency energy for non-invasive health monitoring, a concept that forms the core of the company's proprietary technology. He is joined by CEO John Mastrototaro, a veteran with over 30 years in the medical device industry, notably at Medtronic and MiniMed, where he was pivotal in developing groundbreaking diabetes care products.

The company's business model targets both direct-to-consumer (D2C) and business-to-business (B2B) markets. Revenue is generated through the sale of its wearable devices and future plans include subscription services and partnerships with healthcare providers and insurers. Movano Health is particularly focused on the $40 billion B2B healthcare market, pursuing agreements with pharmaceutical companies and clinical research organizations. The initial market entry product is the Evie Ring, a smart ring specifically designed for women. Launched for commercial sale in November 2023, the Evie Ring is sold directly from the company's website for $269 without a subscription fee and is eligible for HSA/FSA reimbursement.

The Evie Ring is engineered to provide medical-grade accuracy in a consumer device. It tracks a comprehensive set of health metrics, including resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature, sleep stages, and activity levels. A key differentiator is its focus on women's health, offering detailed menstrual cycle, period, and ovulation tracking. The ring itself has an open design made from scratch-resistant Liquidmetal® to accommodate natural fluctuations in finger size. In December 2024, Movano Health achieved a significant milestone by receiving FDA 510(k) clearance for the pulse oximeter in its EvieMED Ring, validating its sensor accuracy and opening doors for B2B applications. The company is also actively developing non-invasive, cuffless blood pressure and continuous glucose monitoring technologies for future integration into its wearable platform.